Search

Your search keyword '"Wander, Seth A."' showing total 339 results
Start Over Author "Wander, Seth A."
339 results on '"Wander, Seth A."'

1. Adjuvant endocrine therapy with cyclin-dependent kinase 4/6 inhibitor, ribociclib, for localized hormone receptor-positive/HER2- breast cancer (LEADER).

Author

Spring, Laura, Scarpetti, Lauren, Medford, Arielle, Niemierko, Andrzej, Comander, Amy, Mulvey, Therese, Schnipper, Lowell, Isakoff, Steven, Moy, Beverly, Wander, Seth, Shin, Jennifer, Ephrem, Zanta, Laposta, Anneke, Denault, Elyssa, Abraham, Elizabeth, Calistro, Gayle, Kalashnikova, Ekaterina, Rodriguez, Angel, Liu, Minetta, Aleshin, Alexey, Peppercorn, Jeffrey, Ellisen, Leif, and Bardia, Aditya

Abstract

Optimal timing and dosing of adjuvant cyclin-dependent kinase (CDK) 4/6 inhibitor in early breast cancer is controversial. This prospective phase II clinical trial investigated tolerability and safety of two ribociclib dosing schedules. Patients with stage I-III hormone receptor-positive (HR+)/HER2- breast cancer on adjuvant endocrine therapy (ET) were randomized to two ribociclib dosing schedules: 400 mg continuous vs 600 mg intermittent, with initiation in early (prior ET

Published
2025

3. Cell cycle dysregulation in cancer

Author

Glaviano, Antonino, Singh, Samarendra K., Lee, E. Hui Clarissa, Okina, Elena, Lam, Hiu Yan, Carbone, Daniela, Reddy, E. Premkumar, O’Connor, Mark J., Koff, Andrew, Singh, Garima, Stebbing, Justin, Sethi, Gautam, Crasta, Karen Carmelina, Diana, Patrizia, Keyomarsi, Khandan, Yaffe, Michael B., Wander, Seth A., Bardia, Aditya, and Kumar, Alan Prem

Published
2025
Full Text
View/download PDF

4. Targeting CDK4 and 6 in Cancer Therapy: Emerging Preclinical Insights Related to Abemaciclib

Author

Wander, Seth A, O’Brien, Neil, Litchfield, Lacey M, O’Dea, Declan, Guimaraes, Claudia Morato, Slamon, Dennis J, and Goel, Shom

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Estrogen, Breast Cancer, Cancer, 5.1 Pharmaceuticals, Development of treatments and therapeutic interventions, Aminopyridines, Benzimidazoles, Breast Neoplasms, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Estrogens, Female, Humans, Mitogens, Protein Kinase Inhibitors, Tumor Suppressor Proteins, abemaciclib, antitumor, breast neoplasms, CDK4 and 6, preclinical, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

Pharmacologic inhibitors of cyclin-dependent kinases 4 and 6 (CDK4 and 6) are approved for the treatment of subsets of patients with hormone receptor positive (HR+) breast cancer (BC). In metastatic disease, strategies involving endocrine therapy combined with CDK4 and 6 inhibitors (CDK4 and 6i) improve clinical outcomes in HR+ BCs. CDK4 and 6i prevent retinoblastoma tumor suppressor protein phosphorylation, thereby blocking the transcription of E2F target genes, which in turn inhibits both mitogen and estrogen-mediated cell proliferation. In this review, we summarize preclinical data pertaining to the use of CDK4 and 6i in BC, with a particular focus on several of the unique chemical, pharmacologic, and mechanistic properties of abemaciclib. As research efforts elucidate the novel mechanisms underlying abemaciclib activity, potential new applications are being identified. For example, preclinical studies have demonstrated abemaciclib can exert antitumor activity against multiple tumor types and can cross the blood-brain barrier. Abemaciclib has also demonstrated distinct activity as a monotherapeutic in the treatment of BC. Accordingly, we also discuss how a greater understanding of mechanisms related to CDK4 and 6 blockade highlight abemaciclib's unique in-class properties, and could pave new avenues for enhancing its therapeutic efficacy.

Published
2022

5. Mechanisms of sensitivity and resistance to CDK4/CDK6 inhibitors in hormone receptor-positive breast cancer treatment

Author

Glaviano, Antonino, Wander, Seth A., Baird, Richard D., Yap, Kenneth C.-H., Lam, Hiu Yan, Toi, Masakazu, Carbone, Daniela, Geoerger, Birgit, Serra, Violeta, Jones, Robert H., Ngeow, Joanne, Toska, Eneda, Stebbing, Justin, Crasta, Karen, Finn, Richard S., Diana, Patrizia, Vuina, Karla, de Bruin, Robertus A.M., Surana, Uttam, Bardia, Aditya, and Kumar, Alan Prem

Published
2024
Full Text
View/download PDF

7. Interplay between ESR1/PIK3CA codon variants, oncogenic pathway alterations and clinical phenotype in patients with metastatic breast cancer (MBC): comprehensive circulating tumor DNA (ctDNA) analysis

Author

Gerratana, Lorenzo, Davis, Andrew A., Velimirovic, Marko, Clifton, Katherine, Hensing, Whitney L., Shah, Ami N., Dai, Charles S., Reduzzi, Carolina, D’Amico, Paolo, Wehbe, Firas, Medford, Arielle, Wander, Seth A., Gradishar, William J., Behdad, Amir, Puglisi, Fabio, Ma, Cynthia X., Bardia, Aditya, and Cristofanilli, Massimo

Published
2023
Full Text
View/download PDF

10. Abemaciclib plus fulvestrant vs fulvestrant alone for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy: Primary outcome of the phase 3 postMONARCH trial.

Author

Kalinsky, Kevin, primary, Bianchini, Giampaolo, additional, Hamilton, Erika P., additional, Graff, Stephanie L., additional, Park, Kyong Hwa, additional, Jeselsohn, Rinath, additional, Demirci, Umut, additional, Martin, Miguel, additional, Layman, Rachel M., additional, Hurvitz, Sara A., additional, Sammons, Sarah L, additional, Kaufman, Peter A., additional, Muñoz, Montserrat, additional, Tseng, Ling-Ming, additional, Knoderer, Holly, additional, Nguyen, Bastien, additional, Zhou, Yanhong, additional, Ravenberg, Elizabeth, additional, Litchfield, Lacey M, additional, and Wander, Seth Andrew, additional

Published
2024
Full Text
View/download PDF

11. Real-world (RW) elacestrant use patterns and therapeutic outcomes in patients (pts) with hormone receptor-positive (HR+)/HER2-negative advanced breast cancer (aBC).

Author

Lloyd, Maxwell Roger, primary, Ali, Azka, additional, Weipert, Caroline M., additional, Solomon, Sheila R, additional, Saha, Jayati, additional, Lipsyc-Sharf, Marla, additional, Hamilton, Erika P., additional, Kalinsky, Kevin, additional, Bardia, Aditya, additional, Zhang, Nicole, additional, and Wander, Seth Andrew, additional

Published
2024
Full Text
View/download PDF

12. Efficacy of subsequent treatments after disease progression on CDK4/6 inhibitors therapy in patients with hormone receptor-positive metastatic breast cancer: A Kaplan-Meier derived individual-patient data meta-analysis.

Author

Ravani, Lis Victoria, primary, Calomeni, Pedro, additional, Vilbert, Maysa, additional, Madeira, Thiago, additional, Wang, Ming, additional, Deng, Daxuan, additional, Testa, Laura, additional, Clifton, Katherine, additional, Wander, Seth Andrew, additional, and Lustberg, Maryam B., additional

Published
2024
Full Text
View/download PDF

13. Sequential combination of sacituzumab govitecan and talazoparib in metastatic triple negative breast cancer (mTNBC): Results from a phase II study.

Author

Abelman, Rachel Occhiogrosso, primary, Spring, Laura, additional, Niemierko, Andrzej, additional, Abraham, Elizabeth, additional, McNeice, Mary, additional, Goff, Jennifer, additional, Valenti, Amanda, additional, Wander, Seth Andrew, additional, Isakoff, Steven J., additional, Moy, Beverly, additional, Juric, Dejan, additional, Vidula, Neelima, additional, Waks, Adrienne Gropper, additional, Parsons, Heather Anne, additional, Ellisen, Leif W., additional, Tolaney, Sara M., additional, and Bardia, Aditya, additional

Published
2024
Full Text
View/download PDF

14. Open-label, randomized, multicenter, phase 3, ELAINE 3 study of the efficacy and safety of lasofoxifene plus abemaciclib for treating ER+/HER2-, locally advanced or metastatic breast cancer with an ESR1 mutation.

Author

Goetz, Matthew P., primary, Wander, Seth Andrew, additional, Bachelot, Thomas, additional, Batist, Gerald, additional, Cortes, Javier, additional, Cristofanilli, Massimo, additional, Curigliano, Giuseppe, additional, de Nonneville, Alexandre, additional, Gal-Yam, Einav Nili, additional, Jhaveri, Komal L., additional, Ma, Cynthia X., additional, Parsons, Heather Anne, additional, Rugo, Hope S., additional, Sammons, Sarah L, additional, Stover, Daniel G., additional, Twelves, Chris, additional, Bardia, Aditya, additional, Plourde, Paul V, additional, Portman, David Jay, additional, and Damodaran, Senthil, additional

Published
2024
Full Text
View/download PDF

15. Interim analysis (IA) of the giredestrant (G) + everolimus (EVERO) arm in MORPHEUS Breast Cancer (BC): A phase I/II study of G treatment (tx) combinations in patients (pts) with estrogen receptor-positive (ER+), HER2-negative, locally advanced/metastatic BC (LA/mBC).

Author

Wander, Seth Andrew, primary, Stemmer, Salomon M., additional, Rugo, Hope S., additional, Im, Seock-Ah, additional, Lau, Peter Kar Han, additional, Paluch-Shimon, Shani, additional, Cahuzac, Clélia, additional, Collier, Annie, additional, Shah, Mona D., additional, Ngo, Huy X., additional, Schwab, Richard B., additional, Zhu, Jing, additional, and Oliveira, Mafalda, additional

Published
2024
Full Text
View/download PDF

17. Cyclin-Dependent Kinase 4/6 Inhibitors Beyond Progression in Metastatic Breast Cancer: A Retrospective Real-World Biomarker Analysis

Author

Gerratana, Lorenzo, Davis, Andrew A., Velimirovic, Marko, Reduzzi, Carolina, Clifton, Katherine, Bucheit, Leslie, Hensing, Whitney L., Shah, Ami N., Pivetta, Tania, Dai, Charles S., DʼAmico, Paolo, Wehbe, Firas, Medford, Arielle, Wander, Seth A., Gradishar, William J., Behdad, Amir, Ma, Cynthia X., Puglisi, Fabio, Bardia, Aditya, and Cristofanilli, Massimo

Published
2023
Full Text
View/download PDF

18. A Gene Panel Associated With Abemaciclib Utility in ESR1-Mutated Breast Cancer After Prior Cyclin-Dependent Kinase 4/6-Inhibitor Progression

Author

Brett, Jamie O., Dubash, Taronish D., Johnson, Gabriela N., Niemierko, Andrzej, Mariotti, Veronica, Kim, Leslie S.L., Xi, Jing, Pandey, Apurva, Dunne, Siobhan, Nasrazadani, Azadeh, Lloyd, Maxwell R., Kambadakone, Avinash, Spring, Laura M., Micalizzi, Douglas S., Onozato, Maristela L., Che, Dante, Nayar, Utthara, Brufsky, Adam, Kalinsky, Kevin, Ma, Cynthia X., OʼShaughnessy, Joyce, Han, Hyo S., Iafrate, Anthony J., Ryan, Lianne Y., Juric, Dejan, Moy, Beverly, Ellisen, Leif W., Maheswaran, Shyamala, Wagle, Nikhil, Haber, Daniel A., Bardia, Aditya, and Wander, Seth A.

Published
2023
Full Text
View/download PDF

19. VERITAC-2: a Phase III study of vepdegestrant, a PROTAC ER degrader, versus fulvestrant in ER+/HER2- advanced breast cancer.

Author

Hamilton, Erika P, Ma, Cynthia, De Laurentiis, Michelino, Iwata, Hiroji, Hurvitz, Sara A, Wander, Seth A, Danso, Michael, Lu, Dongrui R, Perkins Smith, Julia, Liu, Yuan, Tran, Lana, Anderson, Sibyl, and Campone, Mario

Abstract

Vepdegestrant (ARV-471) is an oral PROTAC ER degrader that binds an E3 ubiquitin ligase and ER to directly trigger ubiquitination of ER and its subsequent proteasomal degradation. In a first-in-human Phase I/II study, vepdegestrant monotherapy was well tolerated with clinical activity in pretreated patients with ER+/HER2- advanced breast cancer. The global, randomized Phase III VERITAC-2 study compares efficacy and safety of vepdegestrant versus fulvestrant in adults with ER+/HER2- advanced breast cancer after treatment with a CDK4/6 inhibitor plus endocrine therapy. Progression-free survival by blinded independent central review (primary end point) will be assessed in the intention-to-treat population and ESR1 mutation-positive subpopulation. Secondary end points include overall survival, tumor response, safety, pharmacokinetics, patient-reported outcomes, and circulating tumor DNA biomarkers. Clinical trial registration:NCT05654623 (ClinicalTrials.gov) Plain Language Summary VERITAC-2 is a clinical trial comparing vepdegestrant, a new drug that degrades estrogen receptors, to an existing treatment called fulvestrant in patients with ER+/HER2- advanced breast cancer: Estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer grows in response to estrogen, a hormone in the body, and has low levels or no HER2 protein. People living with ER+/HER2- advanced breast cancer that has grown, spread to another part of the body, or cannot be removed by surgery are often treated with cyclin-dependent kinase (CDK) 4/6 inhibitors and endocrine therapies, but their cancer may get worse on these treatments and new treatments are needed. Fulvestrant, an endocrine therapy that attaches to estrogen receptors, lowers estrogen's effect on tumors and can slow or stop cancer growth. Vepdegestrant, a new medicine being tested for ER+ breast cancer, is a PROteolysis TArgeting Chimera (PROTAC) protein degrader that attaches to estrogen receptors and causes them to be tagged for removal by the cell's natural protein disposal system. By removing estrogen receptors, vepdegestrant may cause tumors to stop growing or shrink. This paper describes the Phase III VERITAC-2 clinical study comparing vepdegestrant versus fulvestrant in people living with ER+/HER2- advanced breast cancer previously treated with a CDK4/6 inhibitor and endocrine therapy. Patients will be randomly assigned to receive vepdegestrant (a pill taken once daily by mouth) or fulvestrant (a shot given into the muscle). The purpose of the study is to find out how long people live without their cancer getting worse with vepdegestrant or fulvestrant. VERITAC-2 will also look at how long people live during the study, side effects people may experience, and the overall well-being of people throughout the study. Article highlights VERITAC-2 study rationale ER-mediated signaling is a key driver of breast cancer pathogenesis in ER+/HER2- breast cancer, which accounts for the majority of all breast cancers. Despite the initial efficacy of first-line treatments that use endocrine therapies (ETs), the acquisition of mutations in ESR1 often leads to the development of ET resistance, leading to disease progression and poor outcomes; there is no clear standard of care in the second-line setting. Vepdegestrant is a small-molecule PROteolysis TArgeting Chimera (PROTAC) ER degrader that has a unique mechanism of action that harnesses the ubiquitin-proteasome system to induce direct ubiquitination and subsequent degradation of ER, unlike selective ER degraders, which lead to conformational changes in ER that may indirectly result in ER degradation. In preclinical studies, vepdegestrant demonstrated potent ER degradation and robust tumor growth inhibition and regression. In a first-in-human Phase I/II dose escalation and cohort expansion clinical study, vepdegestrant was well tolerated and demonstrated antitumor activity; the 200-mg once-daily dose of vepdegestrant was chosen as the recommended Phase III monotherapy dose. VERITAC-2 study design VERITAC-2 is an open-label, randomized, global, multicenter, Phase III study comparing the efficacy and safety of vepdegestrant with fulvestrant in adults with ER+/HER2- advanced breast cancer. Eligible patients have a confirmed diagnosis of ER+/HER2- locoregional recurrent or metastatic breast cancer not amenable to surgical resection or radiation. Patients must also have had one line of prior treatment with CDK4/6 inhibitor therapy in combination with ET and no more than one additional line of ET wherein the most recent ET was given for ≥6 months before disease progression. The primary end point is progression-free survival in both the intention-to-treat population and ESR1 mutation-positive subpopulation, and key secondary end points include overall survival, objective response rate, duration of response, clinical benefit rate, and safety and tolerability end points. This study plans to enroll 560 patients; enrollment is ongoing at the time of publication. Infographic [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

21. CDK4/6 Inhibitor Efficacy in ESR1 -Mutant Metastatic Breast Cancer

Author

Lloyd, Maxwell R., primary, Brett, Jamie O., additional, Carmeli, Ariel, additional, Weipert, Caroline M., additional, Zhang, Nicole, additional, Yu, Junhua, additional, Bucheit, Leslie, additional, Medford, Arielle J., additional, Wagle, Nikhil, additional, Bardia, Aditya, additional, and Wander, Seth A., additional

Published
2024
Full Text
View/download PDF

27. Case 26-2024: A 59-Year-Old Woman with Aphasia, Anemia, and a Breast Mass.

Author

Wander, Seth A., Thai, Janice N., Wirth, Lori J., Soto, Daniel E., Kwait, Rebecca M., and Alzumaili, Bayan A.

Subjects
*ADENOID cystic carcinoma, *LOBULAR carcinoma, *MEDICAL societies, *APHASIA
Abstract

The article focuses on a 59-year-old woman with a longstanding breast lesion and recent neurological symptoms, who was referred to a multidisciplinary breast oncology clinic. Topics include the diagnosis of acute infarction, positive SARS-CoV-2 screening, and imaging findings of a large breast mass with potential metastases and evidence of ischemic stroke.

Published
2024
Full Text
View/download PDF

28. Novel oral selective estrogen receptor degraders (SERDs) to target hormone receptor positive breast cancer: elacestrant as the poster-child.

Author

Keenan, Jennifer C., Medford, Arielle J., Dai, Charles S., Wander, Seth A., Spring, Laura M., and Bardia, Aditya

Subjects
HORMONE receptor positive breast cancer, ESTROGEN receptors, METASTATIC breast cancer, CANCER patients, FULVESTRANT, CYCLIN-dependent kinase inhibitors
Abstract

Estrogen receptor positive (ER+) breast cancer is the most common breast cancer subtype, and therapeutic management relies primarily on inhibiting ER signaling. In the metastatic setting, ER signaling is typically targeted by selective estrogen receptor degraders (SERDs) or aromatase inhibitors (AIs), the latter of which prevent estrogen production. Activating ESR1 mutations are among the most common emergent breast cancer mutations and confer resistance to AIs. Until 2023, fulvestrant was the only approved SERD; fulvestrant is administered intramuscularly, and in some cases may also have limited efficacy in the setting of certain ESR1 mutations. In 2023, the first oral SERD, elacestrant, was approved for use in ESR1-mutated, ER+/HER2- advanced breast cancer and represents a new class of therapeutic options. While the initial approval was as monotherapy, ongoing studies are evaluating elacestrant (as well as other oral SERDs) in combination with other therapies including CDK4/6 inhibitors and PI3K inhibitors, which parallels the current combination uses of fulvestrant. Elacestrant's recent approval sheds light on the use of biomarkers such as ESR1 to gauge a tumor's endocrine sensitivity. Ongoing therapeutic and correlative biomarker studies will offer new insight and expanding treatment options for patients with advanced breast cancer. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

31. Virtual Molecular and Precision Medicine Clinic to Improve Access to Clinical Trials for Patients With Metastatic Breast Cancer: An Academic/Community Collaboration.

Author

Spring, Laura M., Mortensen, Lindsey, Abraham, Elizabeth, Keenan, Jennifer, Medford, Arielle, Ma, Annie, Padden, Sarah, Denault, Elyssa, Ryan, Lianne, Iafrate, A. John, Lennerz, Jochen, Hochberg, Ephraim, Wander, Seth A., Moy, Beverly, Isakoff, Steven J., Juric, Dejan, Brennan, Kimberly A., Smith, Deborah E., Civiello, Barbara, and Mulvey, Therese

Subjects
BREAST tumor treatment, CLINICAL trials, HUMAN research subjects, METASTASIS, GENETIC testing, MEDICAL care, CANCER patients, SURVEYS, HUMAN services programs, CONCEPTUAL structures, QUALITY assurance, MEDICAL referrals, HEALTH care teams, GENOMICS, DATA analysis software, BREAST tumors, TELEMEDICINE
Abstract

PURPOSE There is a demand for improved care delivery surrounding genomic testing and clinical trial enrollment among patients with metastatic breast cancer (MBC). We sought to improve the current process via real-time informal consultation and prescreening assessment for patients with MBC treated by community and academic medical oncologists by implementing a virtual molecular and precision medicine (vMAP) clinic. METHODS The vMAP program used a virtual referral system directed to a multidisciplinary team with precision medicine expertise. Providers contacted vMAP regarding patients with MBC, and on receipt of referral, the vMAP team engaged in discussion to identify if further diagnostics were needed (including genomic testing) and to identify potential clinical trials or standard treatment options. Recommendations were then sent to the referring provider within 72 hours. Pre-/postsurveys were issued to network physicians to assess for barriers, clinical trial access, and vMAP referral experience. Program implementation was evaluated with the Squire 2.0 reporting guidelines for quality improvement in health care as a framework. RESULTS Eighty-one cases from 22 providers were referred to vMAP over a 26-month period. The average response time to the referring provider with a finalized recommendation was 1.90 ± 1.82 days. A total of 86.4% of cases had clinical trial options on vMAP prescreen, with 40.7% initiating formal screening assessments and 27 patients (33.3%) ultimately enrolling on trials. On resurvey, 92% of survey responses across community oncology referring providers said that they were very likely to use vMAP again. CONCLUSION In the initial 2-year period, vMAP demonstrated an efficient means to offer real-time interpretation of genomic testing and identification of clinical trials for patients with MBC, with effective clinical trial enrollment and high rates of referring provider satisfaction. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

32. Supplemental Table 2 from The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor–Positive Metastatic Breast Cancer

Author

Wander, Seth A., primary, Cohen, Ofir, primary, Gong, Xueqian, primary, Johnson, Gabriela N., primary, Buendia-Buendia, Jorge E., primary, Lloyd, Maxwell R., primary, Kim, Dewey, primary, Luo, Flora, primary, Mao, Pingping, primary, Helvie, Karla, primary, Kowalski, Kailey J., primary, Nayar, Utthara, primary, Waks, Adrienne G., primary, Parsons, Stephen H., primary, Martinez, Ricardo, primary, Litchfield, Lacey M., primary, Ye, Xiang S., primary, Yu, Chunping, primary, Jansen, Valerie M., primary, Stille, John R., primary, Smith, Patricia S., primary, Oakley, Gerard J., primary, Chu, Quincy S., primary, Batist, Gerald, primary, Hughes, Melissa E., primary, Kremer, Jill D., primary, Garraway, Levi A., primary, Winer, Eric P., primary, Tolaney, Sara M., primary, Lin, Nancy U., primary, Buchanan, Sean G., primary, and Wagle, Nikhil, primary

Published
2023
Full Text
View/download PDF

33. Supplemental Figure 8 from The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor–Positive Metastatic Breast Cancer

Author

Wander, Seth A., primary, Cohen, Ofir, primary, Gong, Xueqian, primary, Johnson, Gabriela N., primary, Buendia-Buendia, Jorge E., primary, Lloyd, Maxwell R., primary, Kim, Dewey, primary, Luo, Flora, primary, Mao, Pingping, primary, Helvie, Karla, primary, Kowalski, Kailey J., primary, Nayar, Utthara, primary, Waks, Adrienne G., primary, Parsons, Stephen H., primary, Martinez, Ricardo, primary, Litchfield, Lacey M., primary, Ye, Xiang S., primary, Yu, Chunping, primary, Jansen, Valerie M., primary, Stille, John R., primary, Smith, Patricia S., primary, Oakley, Gerard J., primary, Chu, Quincy S., primary, Batist, Gerald, primary, Hughes, Melissa E., primary, Kremer, Jill D., primary, Garraway, Levi A., primary, Winer, Eric P., primary, Tolaney, Sara M., primary, Lin, Nancy U., primary, Buchanan, Sean G., primary, and Wagle, Nikhil, primary

Published
2023
Full Text
View/download PDF

34. Supplemental Table 5 from The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor–Positive Metastatic Breast Cancer

Author

Wander, Seth A., primary, Cohen, Ofir, primary, Gong, Xueqian, primary, Johnson, Gabriela N., primary, Buendia-Buendia, Jorge E., primary, Lloyd, Maxwell R., primary, Kim, Dewey, primary, Luo, Flora, primary, Mao, Pingping, primary, Helvie, Karla, primary, Kowalski, Kailey J., primary, Nayar, Utthara, primary, Waks, Adrienne G., primary, Parsons, Stephen H., primary, Martinez, Ricardo, primary, Litchfield, Lacey M., primary, Ye, Xiang S., primary, Yu, Chunping, primary, Jansen, Valerie M., primary, Stille, John R., primary, Smith, Patricia S., primary, Oakley, Gerard J., primary, Chu, Quincy S., primary, Batist, Gerald, primary, Hughes, Melissa E., primary, Kremer, Jill D., primary, Garraway, Levi A., primary, Winer, Eric P., primary, Tolaney, Sara M., primary, Lin, Nancy U., primary, Buchanan, Sean G., primary, and Wagle, Nikhil, primary

Published
2023
Full Text
View/download PDF

35. Data from The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor–Positive Metastatic Breast Cancer

Author

Wander, Seth A., primary, Cohen, Ofir, primary, Gong, Xueqian, primary, Johnson, Gabriela N., primary, Buendia-Buendia, Jorge E., primary, Lloyd, Maxwell R., primary, Kim, Dewey, primary, Luo, Flora, primary, Mao, Pingping, primary, Helvie, Karla, primary, Kowalski, Kailey J., primary, Nayar, Utthara, primary, Waks, Adrienne G., primary, Parsons, Stephen H., primary, Martinez, Ricardo, primary, Litchfield, Lacey M., primary, Ye, Xiang S., primary, Yu, Chunping, primary, Jansen, Valerie M., primary, Stille, John R., primary, Smith, Patricia S., primary, Oakley, Gerard J., primary, Chu, Quincy S., primary, Batist, Gerald, primary, Hughes, Melissa E., primary, Kremer, Jill D., primary, Garraway, Levi A., primary, Winer, Eric P., primary, Tolaney, Sara M., primary, Lin, Nancy U., primary, Buchanan, Sean G., primary, and Wagle, Nikhil, primary

Published
2023
Full Text
View/download PDF

36. Supplemental Table 6 from The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor–Positive Metastatic Breast Cancer

Author

Wander, Seth A., primary, Cohen, Ofir, primary, Gong, Xueqian, primary, Johnson, Gabriela N., primary, Buendia-Buendia, Jorge E., primary, Lloyd, Maxwell R., primary, Kim, Dewey, primary, Luo, Flora, primary, Mao, Pingping, primary, Helvie, Karla, primary, Kowalski, Kailey J., primary, Nayar, Utthara, primary, Waks, Adrienne G., primary, Parsons, Stephen H., primary, Martinez, Ricardo, primary, Litchfield, Lacey M., primary, Ye, Xiang S., primary, Yu, Chunping, primary, Jansen, Valerie M., primary, Stille, John R., primary, Smith, Patricia S., primary, Oakley, Gerard J., primary, Chu, Quincy S., primary, Batist, Gerald, primary, Hughes, Melissa E., primary, Kremer, Jill D., primary, Garraway, Levi A., primary, Winer, Eric P., primary, Tolaney, Sara M., primary, Lin, Nancy U., primary, Buchanan, Sean G., primary, and Wagle, Nikhil, primary

Published
2023
Full Text
View/download PDF

37. Supplemental Table 3 from The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor–Positive Metastatic Breast Cancer

Author

Wander, Seth A., primary, Cohen, Ofir, primary, Gong, Xueqian, primary, Johnson, Gabriela N., primary, Buendia-Buendia, Jorge E., primary, Lloyd, Maxwell R., primary, Kim, Dewey, primary, Luo, Flora, primary, Mao, Pingping, primary, Helvie, Karla, primary, Kowalski, Kailey J., primary, Nayar, Utthara, primary, Waks, Adrienne G., primary, Parsons, Stephen H., primary, Martinez, Ricardo, primary, Litchfield, Lacey M., primary, Ye, Xiang S., primary, Yu, Chunping, primary, Jansen, Valerie M., primary, Stille, John R., primary, Smith, Patricia S., primary, Oakley, Gerard J., primary, Chu, Quincy S., primary, Batist, Gerald, primary, Hughes, Melissa E., primary, Kremer, Jill D., primary, Garraway, Levi A., primary, Winer, Eric P., primary, Tolaney, Sara M., primary, Lin, Nancy U., primary, Buchanan, Sean G., primary, and Wagle, Nikhil, primary

Published
2023
Full Text
View/download PDF

38. Supplemental Table 8 from The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor–Positive Metastatic Breast Cancer

Author

Wander, Seth A., primary, Cohen, Ofir, primary, Gong, Xueqian, primary, Johnson, Gabriela N., primary, Buendia-Buendia, Jorge E., primary, Lloyd, Maxwell R., primary, Kim, Dewey, primary, Luo, Flora, primary, Mao, Pingping, primary, Helvie, Karla, primary, Kowalski, Kailey J., primary, Nayar, Utthara, primary, Waks, Adrienne G., primary, Parsons, Stephen H., primary, Martinez, Ricardo, primary, Litchfield, Lacey M., primary, Ye, Xiang S., primary, Yu, Chunping, primary, Jansen, Valerie M., primary, Stille, John R., primary, Smith, Patricia S., primary, Oakley, Gerard J., primary, Chu, Quincy S., primary, Batist, Gerald, primary, Hughes, Melissa E., primary, Kremer, Jill D., primary, Garraway, Levi A., primary, Winer, Eric P., primary, Tolaney, Sara M., primary, Lin, Nancy U., primary, Buchanan, Sean G., primary, and Wagle, Nikhil, primary

Published
2023
Full Text
View/download PDF

39. Supplemental Figure 4 from The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor–Positive Metastatic Breast Cancer

Author

Wander, Seth A., primary, Cohen, Ofir, primary, Gong, Xueqian, primary, Johnson, Gabriela N., primary, Buendia-Buendia, Jorge E., primary, Lloyd, Maxwell R., primary, Kim, Dewey, primary, Luo, Flora, primary, Mao, Pingping, primary, Helvie, Karla, primary, Kowalski, Kailey J., primary, Nayar, Utthara, primary, Waks, Adrienne G., primary, Parsons, Stephen H., primary, Martinez, Ricardo, primary, Litchfield, Lacey M., primary, Ye, Xiang S., primary, Yu, Chunping, primary, Jansen, Valerie M., primary, Stille, John R., primary, Smith, Patricia S., primary, Oakley, Gerard J., primary, Chu, Quincy S., primary, Batist, Gerald, primary, Hughes, Melissa E., primary, Kremer, Jill D., primary, Garraway, Levi A., primary, Winer, Eric P., primary, Tolaney, Sara M., primary, Lin, Nancy U., primary, Buchanan, Sean G., primary, and Wagle, Nikhil, primary

Published
2023
Full Text
View/download PDF

40. Supplemental Figure 3 from The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor–Positive Metastatic Breast Cancer

Author

Wander, Seth A., primary, Cohen, Ofir, primary, Gong, Xueqian, primary, Johnson, Gabriela N., primary, Buendia-Buendia, Jorge E., primary, Lloyd, Maxwell R., primary, Kim, Dewey, primary, Luo, Flora, primary, Mao, Pingping, primary, Helvie, Karla, primary, Kowalski, Kailey J., primary, Nayar, Utthara, primary, Waks, Adrienne G., primary, Parsons, Stephen H., primary, Martinez, Ricardo, primary, Litchfield, Lacey M., primary, Ye, Xiang S., primary, Yu, Chunping, primary, Jansen, Valerie M., primary, Stille, John R., primary, Smith, Patricia S., primary, Oakley, Gerard J., primary, Chu, Quincy S., primary, Batist, Gerald, primary, Hughes, Melissa E., primary, Kremer, Jill D., primary, Garraway, Levi A., primary, Winer, Eric P., primary, Tolaney, Sara M., primary, Lin, Nancy U., primary, Buchanan, Sean G., primary, and Wagle, Nikhil, primary

Published
2023
Full Text
View/download PDF

41. Supplemental Figure 6 from The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor–Positive Metastatic Breast Cancer

Author

Wander, Seth A., primary, Cohen, Ofir, primary, Gong, Xueqian, primary, Johnson, Gabriela N., primary, Buendia-Buendia, Jorge E., primary, Lloyd, Maxwell R., primary, Kim, Dewey, primary, Luo, Flora, primary, Mao, Pingping, primary, Helvie, Karla, primary, Kowalski, Kailey J., primary, Nayar, Utthara, primary, Waks, Adrienne G., primary, Parsons, Stephen H., primary, Martinez, Ricardo, primary, Litchfield, Lacey M., primary, Ye, Xiang S., primary, Yu, Chunping, primary, Jansen, Valerie M., primary, Stille, John R., primary, Smith, Patricia S., primary, Oakley, Gerard J., primary, Chu, Quincy S., primary, Batist, Gerald, primary, Hughes, Melissa E., primary, Kremer, Jill D., primary, Garraway, Levi A., primary, Winer, Eric P., primary, Tolaney, Sara M., primary, Lin, Nancy U., primary, Buchanan, Sean G., primary, and Wagle, Nikhil, primary

Published
2023
Full Text
View/download PDF

42. Supplemental Table 7 from The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor–Positive Metastatic Breast Cancer

Author

Wander, Seth A., primary, Cohen, Ofir, primary, Gong, Xueqian, primary, Johnson, Gabriela N., primary, Buendia-Buendia, Jorge E., primary, Lloyd, Maxwell R., primary, Kim, Dewey, primary, Luo, Flora, primary, Mao, Pingping, primary, Helvie, Karla, primary, Kowalski, Kailey J., primary, Nayar, Utthara, primary, Waks, Adrienne G., primary, Parsons, Stephen H., primary, Martinez, Ricardo, primary, Litchfield, Lacey M., primary, Ye, Xiang S., primary, Yu, Chunping, primary, Jansen, Valerie M., primary, Stille, John R., primary, Smith, Patricia S., primary, Oakley, Gerard J., primary, Chu, Quincy S., primary, Batist, Gerald, primary, Hughes, Melissa E., primary, Kremer, Jill D., primary, Garraway, Levi A., primary, Winer, Eric P., primary, Tolaney, Sara M., primary, Lin, Nancy U., primary, Buchanan, Sean G., primary, and Wagle, Nikhil, primary

Published
2023
Full Text
View/download PDF

43. Supplemental Figure 2 from The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor–Positive Metastatic Breast Cancer

Author

Wander, Seth A., primary, Cohen, Ofir, primary, Gong, Xueqian, primary, Johnson, Gabriela N., primary, Buendia-Buendia, Jorge E., primary, Lloyd, Maxwell R., primary, Kim, Dewey, primary, Luo, Flora, primary, Mao, Pingping, primary, Helvie, Karla, primary, Kowalski, Kailey J., primary, Nayar, Utthara, primary, Waks, Adrienne G., primary, Parsons, Stephen H., primary, Martinez, Ricardo, primary, Litchfield, Lacey M., primary, Ye, Xiang S., primary, Yu, Chunping, primary, Jansen, Valerie M., primary, Stille, John R., primary, Smith, Patricia S., primary, Oakley, Gerard J., primary, Chu, Quincy S., primary, Batist, Gerald, primary, Hughes, Melissa E., primary, Kremer, Jill D., primary, Garraway, Levi A., primary, Winer, Eric P., primary, Tolaney, Sara M., primary, Lin, Nancy U., primary, Buchanan, Sean G., primary, and Wagle, Nikhil, primary

Published
2023
Full Text
View/download PDF

44. Supplementary Data from The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor–Positive Metastatic Breast Cancer

Author

Wander, Seth A., primary, Cohen, Ofir, primary, Gong, Xueqian, primary, Johnson, Gabriela N., primary, Buendia-Buendia, Jorge E., primary, Lloyd, Maxwell R., primary, Kim, Dewey, primary, Luo, Flora, primary, Mao, Pingping, primary, Helvie, Karla, primary, Kowalski, Kailey J., primary, Nayar, Utthara, primary, Waks, Adrienne G., primary, Parsons, Stephen H., primary, Martinez, Ricardo, primary, Litchfield, Lacey M., primary, Ye, Xiang S., primary, Yu, Chunping, primary, Jansen, Valerie M., primary, Stille, John R., primary, Smith, Patricia S., primary, Oakley, Gerard J., primary, Chu, Quincy S., primary, Batist, Gerald, primary, Hughes, Melissa E., primary, Kremer, Jill D., primary, Garraway, Levi A., primary, Winer, Eric P., primary, Tolaney, Sara M., primary, Lin, Nancy U., primary, Buchanan, Sean G., primary, and Wagle, Nikhil, primary

Published
2023
Full Text
View/download PDF

45. Supplemental Figure 1 from The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor–Positive Metastatic Breast Cancer

Author

Wander, Seth A., primary, Cohen, Ofir, primary, Gong, Xueqian, primary, Johnson, Gabriela N., primary, Buendia-Buendia, Jorge E., primary, Lloyd, Maxwell R., primary, Kim, Dewey, primary, Luo, Flora, primary, Mao, Pingping, primary, Helvie, Karla, primary, Kowalski, Kailey J., primary, Nayar, Utthara, primary, Waks, Adrienne G., primary, Parsons, Stephen H., primary, Martinez, Ricardo, primary, Litchfield, Lacey M., primary, Ye, Xiang S., primary, Yu, Chunping, primary, Jansen, Valerie M., primary, Stille, John R., primary, Smith, Patricia S., primary, Oakley, Gerard J., primary, Chu, Quincy S., primary, Batist, Gerald, primary, Hughes, Melissa E., primary, Kremer, Jill D., primary, Garraway, Levi A., primary, Winer, Eric P., primary, Tolaney, Sara M., primary, Lin, Nancy U., primary, Buchanan, Sean G., primary, and Wagle, Nikhil, primary

Published
2023
Full Text
View/download PDF

46. Supplemental Table 1 from The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor–Positive Metastatic Breast Cancer

Author

Wander, Seth A., primary, Cohen, Ofir, primary, Gong, Xueqian, primary, Johnson, Gabriela N., primary, Buendia-Buendia, Jorge E., primary, Lloyd, Maxwell R., primary, Kim, Dewey, primary, Luo, Flora, primary, Mao, Pingping, primary, Helvie, Karla, primary, Kowalski, Kailey J., primary, Nayar, Utthara, primary, Waks, Adrienne G., primary, Parsons, Stephen H., primary, Martinez, Ricardo, primary, Litchfield, Lacey M., primary, Ye, Xiang S., primary, Yu, Chunping, primary, Jansen, Valerie M., primary, Stille, John R., primary, Smith, Patricia S., primary, Oakley, Gerard J., primary, Chu, Quincy S., primary, Batist, Gerald, primary, Hughes, Melissa E., primary, Kremer, Jill D., primary, Garraway, Levi A., primary, Winer, Eric P., primary, Tolaney, Sara M., primary, Lin, Nancy U., primary, Buchanan, Sean G., primary, and Wagle, Nikhil, primary

Published
2023
Full Text
View/download PDF

47. Supplemental Figure 9 from The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor–Positive Metastatic Breast Cancer

Author

Wander, Seth A., primary, Cohen, Ofir, primary, Gong, Xueqian, primary, Johnson, Gabriela N., primary, Buendia-Buendia, Jorge E., primary, Lloyd, Maxwell R., primary, Kim, Dewey, primary, Luo, Flora, primary, Mao, Pingping, primary, Helvie, Karla, primary, Kowalski, Kailey J., primary, Nayar, Utthara, primary, Waks, Adrienne G., primary, Parsons, Stephen H., primary, Martinez, Ricardo, primary, Litchfield, Lacey M., primary, Ye, Xiang S., primary, Yu, Chunping, primary, Jansen, Valerie M., primary, Stille, John R., primary, Smith, Patricia S., primary, Oakley, Gerard J., primary, Chu, Quincy S., primary, Batist, Gerald, primary, Hughes, Melissa E., primary, Kremer, Jill D., primary, Garraway, Levi A., primary, Winer, Eric P., primary, Tolaney, Sara M., primary, Lin, Nancy U., primary, Buchanan, Sean G., primary, and Wagle, Nikhil, primary

Published
2023
Full Text
View/download PDF

48. Supplemental Figure 5 from The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor–Positive Metastatic Breast Cancer

Author

Wander, Seth A., primary, Cohen, Ofir, primary, Gong, Xueqian, primary, Johnson, Gabriela N., primary, Buendia-Buendia, Jorge E., primary, Lloyd, Maxwell R., primary, Kim, Dewey, primary, Luo, Flora, primary, Mao, Pingping, primary, Helvie, Karla, primary, Kowalski, Kailey J., primary, Nayar, Utthara, primary, Waks, Adrienne G., primary, Parsons, Stephen H., primary, Martinez, Ricardo, primary, Litchfield, Lacey M., primary, Ye, Xiang S., primary, Yu, Chunping, primary, Jansen, Valerie M., primary, Stille, John R., primary, Smith, Patricia S., primary, Oakley, Gerard J., primary, Chu, Quincy S., primary, Batist, Gerald, primary, Hughes, Melissa E., primary, Kremer, Jill D., primary, Garraway, Levi A., primary, Winer, Eric P., primary, Tolaney, Sara M., primary, Lin, Nancy U., primary, Buchanan, Sean G., primary, and Wagle, Nikhil, primary

Published
2023
Full Text
View/download PDF

49. Supplemental Figure 7 from The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor–Positive Metastatic Breast Cancer

Author

Wander, Seth A., primary, Cohen, Ofir, primary, Gong, Xueqian, primary, Johnson, Gabriela N., primary, Buendia-Buendia, Jorge E., primary, Lloyd, Maxwell R., primary, Kim, Dewey, primary, Luo, Flora, primary, Mao, Pingping, primary, Helvie, Karla, primary, Kowalski, Kailey J., primary, Nayar, Utthara, primary, Waks, Adrienne G., primary, Parsons, Stephen H., primary, Martinez, Ricardo, primary, Litchfield, Lacey M., primary, Ye, Xiang S., primary, Yu, Chunping, primary, Jansen, Valerie M., primary, Stille, John R., primary, Smith, Patricia S., primary, Oakley, Gerard J., primary, Chu, Quincy S., primary, Batist, Gerald, primary, Hughes, Melissa E., primary, Kremer, Jill D., primary, Garraway, Levi A., primary, Winer, Eric P., primary, Tolaney, Sara M., primary, Lin, Nancy U., primary, Buchanan, Sean G., primary, and Wagle, Nikhil, primary

Published
2023
Full Text
View/download PDF

50. Supplemental Table 4 from The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor–Positive Metastatic Breast Cancer

Author

Wander, Seth A., primary, Cohen, Ofir, primary, Gong, Xueqian, primary, Johnson, Gabriela N., primary, Buendia-Buendia, Jorge E., primary, Lloyd, Maxwell R., primary, Kim, Dewey, primary, Luo, Flora, primary, Mao, Pingping, primary, Helvie, Karla, primary, Kowalski, Kailey J., primary, Nayar, Utthara, primary, Waks, Adrienne G., primary, Parsons, Stephen H., primary, Martinez, Ricardo, primary, Litchfield, Lacey M., primary, Ye, Xiang S., primary, Yu, Chunping, primary, Jansen, Valerie M., primary, Stille, John R., primary, Smith, Patricia S., primary, Oakley, Gerard J., primary, Chu, Quincy S., primary, Batist, Gerald, primary, Hughes, Melissa E., primary, Kremer, Jill D., primary, Garraway, Levi A., primary, Winer, Eric P., primary, Tolaney, Sara M., primary, Lin, Nancy U., primary, Buchanan, Sean G., primary, and Wagle, Nikhil, primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results